Back HIV/AIDS

HIV / AIDS

CROI 2017: Several New Candidates in HIV Drug Pipeline Discussed at Conference

This year's Conference on Retroviruses and Opportunistic Infections (CROI), held last month in Seattle, included presentations on several new investigational antiretroviral drugs in development, reflecting a more robust pipeline than we have seen in recent years.

alt

CROI 2017: Timothy Brown, the Berlin Patient, Celebrates a Decade Cured of HIV

Participants at a Community HIV Cure Research Workshop on February 12, in advance of the Conference on Retroviruses and Opportunistic Infections in Seattle, held a "birthday" party for Timothy Ray Brown -- formerly known as the Berlin Patient -- to celebrate 10 years since the bone marrow transplant that would lead to the only known cure for HIV.

alt

CROI 2017: Treatment-as-Prevention Study Sees Substantial Drug Resistance, but No Impact on HIV Therapy

A study of the prevalence of transmitted drug resistance among participants in the ANRS 12249 trial of treatment as prevention, has found that a substantial minority of participants had HIV with drug resistance mutations. However, there was no evidence that pre-existing drug resistance had any impact on the success of treatment, according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt

CROI 2017: Bone Marrow Transplant Patient Off ART for 288 Days Without HIV Rebound

A HIV-positive bone marrow transplant recipient at the Mayo Clinic experienced prolonged viral remission lasting nearly 10 months -- longer than the so-called Boston patients -- after interrupting antiretroviral therapy (ART), according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle. Although his viral load eventually rebounded, his HIV reservoirs appeared to be reduced.

alt

CROI 2017: How Should HIV Self-Testing Be Provided?

At a session on HIV self-testing at the Conference on Retroviruses and Opportunistic Infections this month in Seattle, researchers presented findings from studies looking at some of the unanswered questions about self-testing and how best to implement it, with examples from Malawi and the United States.

alt

CROI 2017: Time with Transmissible HIV Viral Load Has Fallen By Three-Quarters Since 2000

A study by the Centers for Disease Control and Prevention (CDC) presented at the recent Conference on Retroviruses and Opportunistic Infections in Seattle found that the proportion of time people with HIV in the U.S. spend in care but not virally suppressed has fallen from 40% to 10% in the last 15 years. The study also found that young people, black people, and people with public rather than private health coverage spent less time with viral load below 1500 copies/mL, the World Health Organization (WHO) threshold for HIV transmission.

alt

CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies

A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer a new potent and long-acting treatment option if it continues to look promising in larger studies, according to a presentation at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

alt